Certis provides high-precision translational drug discovery and development services to therapeutics innovators.
June 29 SAN DIEGO, CA—Certis Oncology Solutions, a precision oncology and translational science company, announced that it has been awarded accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International). This voluntary and internationally recognized accreditation reflects the company’s commitment to go beyond standards required by regulatory agencies to achieve excellence in animal care and use.
“This is another important milestone for Certis, said CEO, Peter Ellman. “Securing AAALAC accreditation signals to pharmaceutical clients that we are a mature partner with robust and scalable quality systems, and that we are committed to animal use best practices.”
Certis provides high-precision translational drug discovery and development services to therapeutics innovators. Since the launch of its pharmaceutical services offering 18 months ago, the company has partnered with more than 50 oncology-focused drug developers. Unlike most preclinical contract research organizations (CROs), Certis has a precision medicine focus, and also has received CLIA certification from the Centers for Medicare & Medicaid Services—an accreditation that enables the company to accept human biological specimens for diagnostic testing.
“Our direct connection to the clinic is an important differentiator for Certis,” said Ellman. “It not only allows us to provide functional precision oncology directly to patients, our CLIA status facilitates the conduct of co-clinical trials, which employ mouse avatars of patients enrolled in trials to expedite clinical development.”
To receive AAALAC International accreditation, an institution must submit a detailed program description that details all aspects of its animal care and use. Once the program description is reviewed, AAALAC International conducts a comprehensive, onsite assessment of the program and facilities to determine if the institution will be awarded accreditation.
ABOUT CERTIS ONCOLOGY SOLUTIONS
Certis is a life science technology company that delivers highly predictive therapeutic response data derived from proprietary models of cancer. Operating a CLIA-certified and AAALAC-accredited laboratory in San Diego, California, Certis delivers clinically relevant data that informs treatment decisions, empowers cancer patients, and reduces drug development risk. Its mission is to connect every patient to the right therapy for their cancer—the first time, every time. Its vision is a future where cancer is powerless against science.
For more information, contact
Kristein King 573-818-4528 (mobile)